Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2022JCO Precision Oncology

Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

DBDébora S. BrunoCity Of Hope National Medical CenterLHLisa M. HessEli Lilly (United States)XLXiaohong LiZhejiang Chinese Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bruno et al. (2022) studied this question.

synapsesocial.com/papers/6a6f78d02163a0a01bc3c2aahttps://doi.org/10.1200/po.21.00427
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Racial Differences in BRAF / KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients2015 · 115 citations
  2. 2Clinical Impact of Adherence to NCCN Guidelines for Biomarker Testing and First-Line Treatment in Advanced Non-Small Cell Lung Cancer (aNSCLC) Using Real-World Electronic Health Record Data2021 · 43 citations
  3. 3Participation in Cancer Clinical Trials2004 · 2,101 citations
  4. 4The Effect of Advances in Lung-Cancer Treatment on Population Mortality2020 · 1,799 citations
  5. 5Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists2021 · 30 citations